ArticleMediators of inflammation2026
LDHA, BIK, and CNIH4 Are Diagnostic Markers of Endoplasmic Reticulum Stress in Lung Cancer Comorbid With Sepsis: Integrating Machine Learning and Single-Cell Analysis of Immune Signaling.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLung cancer is intricately associated with the onset of sepsis. Endoplasmic reticulum (ER) stress (ERS) is a cellular stress response to aberrant protein folding in the ER, closely associated with the cellular immune response. Currently, numerous research have elucidated the correlation between ERS and lung cancer, as well as sepsis. The mechanism of ERS in lung cancer comorbid with sepsis requires more investigation.
objectivesThis study aimed to investigate the interacting mechanisms between ERS and the immune response, explore prospective ERS-related diagnostic biomarkers for lung cancer comorbid with sepsis, and elucidate their underlying pathological roles.
methodsDatasets for lung cancer and sepsis were sourced from the Gene Expression Omnibus (GEO). Differentially expressed genes (DEGs) and weighted gene coexpression network analysis (WGCNA) modules were intersected with ERS-related genes. Protein-protein interaction (PPI) and enrichment analyses were conducted. A genetic diagnostic model was developed using exhaustive machine learning algorithms, with accuracy assessed by receiver operating characteristic (ROC) curves and confusion matrices. Hub genes (area under the curve [AUC] ≥ 0.7) were analyzed for immune cell infiltration and cross-validated using single-cell RNA sequencing datasets. Crucially, the expression and functional roles of the hub genes were experimentally validated by western blot in clinical tissue cohorts (adjacent normal, lung cancer, and lung cancer with sepsis) and via wound healing and Transwell assays in PC9 lung cancer cells. Finally, prospective therapeutic agents were identified through molecular docking.
resultsMachine learning identified lactate dehydrogenase A (LDHA), Bcl-2 interacting killer (BIK), and cornichon homolog 4 (CNIH4) as robust diagnostic biomarkers. Western blot analysis confirmed that the protein expression levels of LDHA, BIK, and CNIH4 were significantly upregulated in lung cancer and further elevated in the lung cancer comorbid with sepsis group. In vitro functional assays demonstrated that silencing these genes significantly inhibited the migration and invasion capabilities of PC9 cells. Single-cell analysis revealed that these markers exhibit cell-type-specific expression in malignant cells and regulate immune dysregulation, particularly correlating with the functions of plasma cells and monocytes. Molecular docking indicated that tetrahydro-NAD and amikacin are promising therapeutic candidates.
conclusionsWe identified and experimentally validated LDHA, BIK, and CNIH4 as specific ERS-associated diagnostic biomarkers for lung cancer comorbid with sepsis. These markers drive tumor progression and modulate cellular immune responses, providing novel insights and therapeutic targets for this comorbidity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.